Results 21 to 30 of about 31,418 (244)

Cancer cachexia [PDF]

QJM: An International Journal of Medicine, 2005
Cancer cachexia is a severe debilitating disorder for which there are currently few therapeutic options. It is driven by the release of pro-inflammatory cytokines and cachectic factors by both host and tumour. Over the past few years, basic science advances have begun to reveal the breadth and complexity of the immunological mechanisms involved, and in
J N, Gordon, S R, Green, P M, Goggin
openaire   +2 more sources

Associations of low hand grip strength with 1 year mortality of cancer cachexia: a multicentre observational study

Journal of Cachexia, Sarcopenia and Muscle, 2021
Backgrounds Hand grip strength (HGS) is one of diagnose criteria factors of sarcopenia and is associated with the survival of patients with cancer. However, few studies have addressed the association of HGS and 1 year mortality of patients with cancer ...
Mengmeng Song, Qi Zhang, Meng Tang, Xi Zhang, Guotian Ruan, Xiaowei Zhang, Kangping Zhang, Yizhong Ge, Ming Yang, Qinqin Li, Xiangrui Li, Xiaoyue Liu, Wei Li, Minghua Cong, Kunhua Wang, Chunhua Song, Hanping Shi   +16 more
doaj   +1 more source

Cachexia in Cancer Patients: Systematic Literature Review

Asian Journal of Oncology, 2020
Introduction Cachexia in cancer patients, especially in advanced stage, is recently known as an emerging problem. Cachexia occurs in about half of all patients with neoplastic disease.
Timotius I. Hariyanto, Andree Kurniawan
doaj   +1 more source

Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study

OncoImmunology, 2021
Although previous studies suggest that cancer cachexia is a poor prognostic factor for immune checkpoint inhibitor monotherapy, the impact of cancer cachexia on chemoimmunotherapy is unclear.
Kenji Morimoto, Junji Uchino, Takashi Yokoi, Takashi Kijima, Yasuhiro Goto, Akira Nakao, Makoto Hibino, Takayuki Takeda, Hiroyuki Yamaguchi, Chieko Takumi, Masafumi Takeshita, Yusuke Chihara, Takahiro Yamada, Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Tadaaki Yamada, Koichi Takayama   +18 more
doaj   +1 more source

Mediators and clinical treatment for cancer cachexia: a systematic review

JCSM Rapid Communications, 2021
Background Cachexia, a complex multi‐organ syndrome, shortens survival time of patients, particularly those with cancer. Many studies and clinical trials have been carried out to identify cachexia‐inducing factors and potential treatments for cancer ...
Zhipeng Cao, Andrew M. Scott, Nick J. Hoogenraad, Laura D. Osellame   +3 more
doaj   +1 more source

Prognostic effect of cachexia in patients with non‐small cell lung cancer receiving immune checkpoint inhibitors

Thoracic Cancer, 2023
Background The presence of cachexia in cancer patients negatively affects the quality of life and survival. However, the impact of cachexia on immunotherapy, such as PD‐1/L1 inhibitors, is not fully understood.
Norikazu Matsuo, Koichi Azuma, Kenta Murotani, Daiki Murata, Goushi Matama, Akihiko Kawahara, Takashi Kojima, Takaaki Tokito, Tomoaki Hoshino   +8 more
doaj   +1 more source

Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors

Cancer Medicine, 2023
Background The presence of cachexia negatively impacts the prognosis of patients with cancer. However, the mechanisms behind the development of cachexia and its prognostic impact on immunotherapy efficacy are not fully understood.
Daiki Murata, Koichi Azuma, Norikazu Matsuo, Kenta Murotani, Goushi Matama, Akihiko Kawahara, Tetsuro Sasada, Takaaki Tokito, Tomoaki Hoshino   +8 more
doaj   +1 more source

Babao Dan Alleviates Cancer Cachexia in Mice Via Inhibiting IL-6/STAT3 Signaling Pathway

Integrative Cancer Therapies, 2023
Background: Cancer cachexia is a common but severe condition that causes muscle wasting, body weight loss, and progressive functional impairment, affecting over 50% of cancer patients.
Zhengliang Qiu BS, Da Wo PhD, Xiaomei Zhong BS, Jinxiao Chen PhD, En Ma MS, Jia He PhD, Jun Peng MD, PhD, Weidong Zhu MD, PhD, Dan-ni Ren MD, PhD   +8 more
doaj   +1 more source

Circulating monocyte chemoattractant protein‐1 (MCP‐1) is associated with cachexia in treatment‐naïve pancreatic cancer patients

Journal of Cachexia, Sarcopenia and Muscle, 2018
Background Cancer‐associated wasting, termed cancer cachexia, has a profound effect on the morbidity and mortality of cancer patients but remains difficult to recognize and diagnose.
Erin E. Talbert, Heather L. Lewis, Matthew R. Farren, Mitchell L. Ramsey, Jeffery M. Chakedis, Priyani Rajasekera, Ericka Haverick, Angela Sarna, Mark Bloomston, Timothy M. Pawlik, Teresa A. Zimmers, Gregory B. Lesinski, Phil A. Hart, Mary E. Dillhoff, Carl R. Schmidt, Denis C. Guttridge   +15 more
doaj   +1 more source

Oncometabolite D-2-hydroxyglutarate—dependent metabolic reprogramming induces skeletal muscle atrophy during cancer cachexia

Communications Biology, 2023
Cancer cachexia is characterized by weight loss and skeletal muscle wasting. Based on the up-regulation of catabolism and down-regulation of anabolism, here we showed genetic mutation-mediated metabolic reprogramming in the progression of cancer cachexia
Xinting Zhu, Juan Hao, Hong Zhang, Mengyi Chi, Yaxian Wang, Jinlu Huang, Rong Xu, Zhao Xincai, Bo Xin, Xipeng Sun, Jianping Zhang, Shumin Zhou, Dongdong Cheng, Ting Yuan, Jun Ding, Shuier Zheng, Cheng Guo, Quanjun Yang   +17 more
doaj   +1 more source